Relationship between dietary inflammatory index and metabolic dysfunction associated steatotic liver disease in children

被引:0
|
作者
Amiri, Fateme [1 ]
Moludi, Jalal [1 ]
Jouybari, Touraj Ahmadi [2 ]
Qasemi, Mahmoud [3 ]
Sharifi, Maryam [1 ]
Mahaki, Behzad [4 ]
Soleimani, Davood [1 ]
机构
[1] Kermanshah Univ Med Sci, Sch Nutr Sci & Food Technol, Dept Nutr Sci, Kermanshah, Iran
[2] Kermanshah Univ Med Sci, Imam Khomeini & Mohammad Kermanshahi & Farabi Hosp, Clin Res Dev Ctr, Kermanshah, Iran
[3] Kermanshah Univ Med Sci, Sch Med, Dept Pediat, Kermanshah, Iran
[4] Kermanshah Univ Med Sci, Sch Hlth, Dept Biostat, Kermanshah, Iran
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
关键词
Non-alcoholic fatty liver disease; Fibrosis; Diet; Inflammation; Pediatrics; NONALCOHOLIC FATTY LIVER; METAANALYSIS; NUTRIENTS; PATTERN; RISK;
D O I
10.1038/s41598-025-89690-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Emerging research suggests a connection between dietary habits and metabolic dysfunction associated steatotic liver disease (MASLD). We aimed to assess the relationship between the Dietary Inflammatory Index (DII) and the severity of MASLD. This cross-sectional study involved 125 participants aged 7-18 with MASLD. Dietary intakes were assessed using a validated 147-item food frequency questionnaire. The DII was applied to measure diet-induced inflammation, categorizing diets into anti-inflammatory (DII < -1) and inflammatory diets (DII > + 1). To evaluate hepatic steatosis and fibrosis, transabdominal ultrasonography and the fibrosis-4 (FIB-4) index were utilized. After adjusting for potential confounding factors, individuals on inflammatory diets exhibited a significantly higher odds ratio (OR) for experiencing more severe steatosis (OR: 4.11; 95% CI: 1.08-15.71) compared to those on anti-inflammatory diets. Furthermore, each unit increase in DII scores was linked to a 2.6-fold increase in the odds of more severe steatosis (OR: 2.61; 95% CI: 1.28-5.32) and a 0.006 increase in FIB-4 scores (beta: 0.006; 95% CI: 0.003-0.011). In conclusion, modifying dietary intakes to lower DII scores may be a beneficial approach to improving clinical outcomes in pediatric MASLD, as anti-inflammatory diets are associated with reduced severity of hepatic steatosis and fibrosis.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Kashihara, Takanori
    Shinomiya, Ryo
    Miyake, Takanori
    Kawaguchi, Tomoyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Kida, Yoshifumi
    Okada, Yasuyuki
    Tomonari, Tetsu
    Kawano, Yutaka
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1587 - 1598
  • [42] Longitudinal Links between Changes in Body Composition and Liver Disease Severity in Children and Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Speakman, Alexandria
    Hitchcock, Kathryn
    Romantic, Emily
    Quiambao, Venancio
    Lepolt, Abigail
    Ley, Sanita
    Arce-Clachar, Ana Catalina
    Bramlage, Kristin
    Fei, Lin
    Sun, Qin
    Xanthakos, Stavra
    Mouzaki, Marialena
    JOURNAL OF PEDIATRICS, 2025, 276
  • [43] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [44] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [45] Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction
    Keingeski, Melina Belen
    Longo, Larisse
    Brum da Silva Nunes, Vitoria
    Figueiro, Fabricio
    Dallemole, Danieli Rosane
    Pohlmann, Adriana Raffin
    Vier Schmitz, Thalia Michele
    da Costa Lopez, Patricia Luciana
    Alvares-da-Silva, Mario Reis
    Uribe-Cruz, Carolina
    METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (05) : 394 - 401
  • [46] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [47] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [48] Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)
    Canivet, C. M.
    Faure, S.
    REVUE DE MEDECINE INTERNE, 2024, 45 (01): : 41 - 47
  • [49] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [50] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146